Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial

被引:50
作者
Denkinger, Claudia M. [1 ,2 ]
Janssen, Maike [3 ]
Schaekel, Ulrike [3 ]
Gall, Julia [4 ,5 ]
Leo, Albrecht [6 ]
Stelmach, Patrick [3 ]
Weber, Stefan F. [1 ]
Krisam, Johannes [7 ]
Baumann, Lukas [7 ]
Stermann, Jacek [7 ]
Merle, Uta [8 ]
Weigand, Markus A. [9 ]
Nusshag, Christian [10 ]
Bullinger, Lars [11 ]
Schrezenmeier, Jens-Florian [11 ]
Bornhaeuser, Martin [12 ,13 ]
Alakel, Nael [12 ,13 ]
Witzke, Oliver [14 ]
Wolf, Timo [15 ]
Vehreschild, Maria J. G. T. [15 ]
Schmiedel, Stefan [16 ]
Addo, Marylyn M. [16 ,17 ,18 ]
Herth, Felix [19 ,20 ]
Kreuter, Michael [21 ,22 ]
Tepasse, Phil-Robin [23 ]
Hertenstein, Bernd [24 ]
Haenel, Mathias [25 ]
Morgner, Anke [25 ]
Kiehl, Michael [26 ]
Hopfer, Olaf [26 ]
Wattad, Mohammad-Amen [27 ]
Schimanski, Carl C. [28 ]
Celik, Cihan [28 ]
Pohle, Thorsten [29 ]
Ruhe, Matthias [29 ]
Kern, Winfried, V [30 ]
Schmitt, Anita [3 ]
Lorenz, Hanns-Martin [3 ]
Souto-Carneiro, Margarida [3 ]
Gaeddert, Mary [1 ]
Halama, Niels [31 ,32 ,33 ]
Meuer, Stefan [6 ]
Kraeusslich, Hans-Georg [34 ]
Mueller, Barbara [34 ]
Schnitzler, Paul [34 ]
Parthe, Sylvia [34 ]
Bartenschlager, Ralf [35 ]
Gronkowski, Martina [3 ]
Klemmer, Jennifer [3 ]
Schmitt, Michael [3 ]
机构
[1] Heidelberg Univ Hosp, Dept Infect Dis, Div Infect Dis & Trop Med, Heidelberg, Germany
[2] German Ctr Infect Res, Partner Site Heidelberg Univ Hosp, Heidelberg, Germany
[3] Heidelberg Univ Hosp, Dept Internal Med 5, Heidelberg, Germany
[4] Heidelberg Univ Hosp, NCT Trial Ctr, Natl Ctr Tumor Dis, Heidelberg, Germany
[5] German Canc Res Ctr, Heidelberg, Germany
[6] Inst Clin Transfus Med & Cell Therapy Heidelberg, Heidelberg, Germany
[7] Heidelberg Univ, Inst Med Biometry, Heidelberg, Germany
[8] Heidelberg Univ Hosp, Dept Internal Med 4, Heidelberg, Germany
[9] Heidelberg Univ Hosp, Dept Anesthesiol, Heidelberg, Germany
[10] Heidelberg Univ, Dept Nephrol, Heidelberg, Germany
[11] Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany
[12] Tech Univ Dresden, Dept Internal Med 1, Univ Hosp Dresden, Dresden, Germany
[13] Tech Univ Dresden, Fac Med Carl Gustav Carus, Dresden, Germany
[14] Univ Duisburg Essen, Univ Hosp Essen, West German Ctr Infect Dis, Dept Infect Dis, Essen, Germany
[15] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Internal Med, Infect Dis, Frankfurt, Germany
[16] Univ Med Ctr Hamburg Eppendorf, Dept Med, Hamburg, Germany
[17] German Ctr Infect Res, Partner Site Hamburg Lubeck Borstel Riems, Hamburg, Germany
[18] Univ Med Ctr Hamburg Eppendorf, Inst Infect Res & Vaccine Dev, Hamburg, Germany
[19] Heidelberg Univ, Thoraxklin, Pneumol & Crit Care Med, Heidelberg, Germany
[20] Translat Lung Res Ctr, Heidelberg, Germany
[21] Heidelberg Univ, Ctr Interstitial & Rare Lung Dis, Thoraxklin, Pneumol & Crit Care Med, Heidelberg, Germany
[22] German Ctr Lung Res, Heidelberg, Germany
[23] Univ Hosp Muster, Dept Med Gastroenterol & Hepatol B, Munster, Germany
[24] Klinikum Bremen Mitte, Med Dept 1, Bremen, Germany
[25] Klinikum Chemnitz, Dept Internal Med 3, Chemnitz, Germany
[26] Frankfurt Oder Gen Hosp, Dept Internal Med 1, Frankfurt, Germany
[27] Klinikum Hochsauerland, Dept Hematol Oncol Palliat Care & Stem Cell Trans, Meschede, Germany
[28] Klinikum Darmstadt, Dept Internal Med 2, Darmstadt, Germany
[29] Klinikum Herford, Dept Internal Med 1, Herford, Germany
[30] Univ Med Ctr Freiburg, Dept Med 2, Div Infect Dis & Travel Med, Freiburg, Germany
[31] Heidelberg Univ Hosp, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany
[32] German Canc Res Ctr, Dept Translat Immunotherapy D24O, Heidelberg, Germany
[33] Helmholtz Inst Translat Oncol, Mainz, Germany
[34] Heidelberg Univ Hosp, Dept Infect Dis, Virol, Heidelberg, Germany
[35] Heidelberg Univ Hosp, Dept Infect Dis, Mol Virol, Heidelberg, Germany
[36] Natl Ctr Tumor Dis, Heidelberg, Germany
关键词
D O I
10.1038/s43018-022-00503-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), with high morbidity and mortality. Furthermore, impaired humoral response renders severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines less effective and treatment options are scarce. Randomized trials using convalescent plasma are missing for high-risk patients. Here, we performed a randomized, open-label, multicenter trial () in hospitalized patients with severe COVID-19 (n = 134) within four risk groups ((1) cancer (n = 56); (2) immunosuppression (n = 16); (3) laboratory-based risk factors (n = 36); and (4) advanced age (n = 26)) randomized to standard of care (control arm) or standard of care plus convalescent/vaccinated anti-SARS-CoV-2 plasma (plasma arm). No serious adverse events were observed related to the plasma treatment. Clinical improvement as the primary outcome was assessed using a seven-point ordinal scale. Secondary outcomes were time to discharge and overall survival. For the four groups combined, those receiving plasma did not improve clinically compared with those in the control arm (hazard ratio (HR) = 1.29; P = 0.205). However, patients with cancer experienced a shortened median time to improvement (HR = 2.50; P = 0.003) and superior survival with plasma treatment versus the control arm (HR = 0.28; P = 0.042). Neutralizing antibody activity increased in the plasma cohort but not in the control cohort of patients with cancer (P = 0.001). Taken together, convalescent/vaccinated plasma may improve COVID-19 outcomes in patients with cancer who are unable to intrinsically generate an adequate immune response.
引用
收藏
页码:96 / +
页数:20
相关论文
共 37 条
[1]   COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study [J].
Avouac, Jerome ;
Drumez, Elodie ;
Hachulla, Eric ;
Seror, Raphaele ;
Georgin-Lavialle, Sophie ;
El Mahou, Soumaya ;
Pertuiset, Edouard ;
Thao Pham ;
Marotte, Hubert ;
Servettaz, Amelie ;
Domont, Fanny ;
Chazerain, Pascal ;
Devaux, Mathilde ;
Claudepierre, Pascal ;
Langlois, Vincent ;
Mekinian, Arsene ;
Maria, Alexandre Thibault Jacques ;
Banneville, Beatrice ;
Fautrel, Bruno ;
Pouchot, Jacques ;
Thomas, Thierry ;
Flipo, Rene-Marc ;
Richez, Christophe .
LANCET RHEUMATOLOGY, 2021, 3 (06) :E419-E426
[2]   COVID-19 and Solid Organ Transplantation: A Review Article [J].
Azzi, Yorg ;
Bartash, Rachel ;
Scalea, Joseph ;
Loarte-Campos, Pablo ;
Akalin, Enver .
TRANSPLANTATION, 2021, 105 (01) :37-55
[3]   Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial) [J].
Bajpai, Meenu ;
Maheshwari, Ashish ;
Dogra, Vikas ;
Kumar, Suresh ;
Gupta, Ekta ;
Kale, Pratibha ;
Saluja, Vandana ;
Thomas, Sherin S. ;
Trehanpati, Nirupama ;
Bihari, Chhagan ;
Agarwal, Reshu ;
Bharti, Praveen ;
Shankar, Prabha ;
Hussain, Javid ;
Chhabra, Karan ;
Gupta, Amita ;
Narayanan, Ashad ;
Agarwal, Sarika ;
Jain, Shruti ;
Bhardwaj, Ankit ;
Kumar, Guresh ;
Yadav, Birendra Kumar ;
Sarin, Shiv Kumar .
BMJ OPEN, 2022, 12 (04)
[4]   Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial [J].
Begin, Philippe ;
Callum, Jeannie ;
Jamula, Erin ;
Cook, Richard ;
Heddle, Nancy M. ;
Tinmouth, Alan ;
Zeller, Michelle P. ;
Beaudoin-Bussieres, Guillaume ;
Amorim, Luiz ;
Bazin, Renee ;
Loftsgard, Kent Cadogan ;
Carl, Richard ;
Chasse, Michael ;
Cushing, Melissa M. ;
Daneman, Nick ;
Devine, Dana, V ;
Dumaresq, Jeannot ;
Fergusson, Dean A. ;
Gabe, Caroline ;
Glesby, Marshall J. ;
Li, Na ;
Liu, Yang ;
McGeer, Allison ;
Robitaille, Nancy ;
Sachais, Bruce S. ;
Scales, Damon C. ;
Schwartz, Lisa ;
Shehata, Nadine ;
Turgeon, Alexis F. ;
Wood, Heidi ;
Zarychanski, Ryan ;
Finzi, Andres ;
Arnold, Donald M. .
NATURE MEDICINE, 2021, 27 (11) :2012-+
[5]   Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients [J].
Benning, Louise ;
Morath, Christian ;
Bartenschlager, Marie ;
Kim, Heeyoung ;
Reineke, Marvin ;
Beimler, Jorg ;
Buylaert, Mirabel ;
Nusshag, Christian ;
Kaelble, Florian ;
Reichel, Paula ;
Toellner, Maximilian ;
Schaier, Matthias ;
Klein, Katrin ;
Benes, Vladimir ;
Rausch, Tobias ;
Rieger, Susanne ;
Stich, Maximilian ;
Toenshoff, Burkhard ;
Weidner, Niklas ;
Schnitzler, Paul ;
Zeier, Martin ;
Susal, Caner ;
Tran, Thuong Hien ;
Bartenschlager, Ralf ;
Speer, Claudius .
AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 (07) :1873-1883
[6]   Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020) [J].
Bhimraj, Adarsh ;
Morgan, Rebecca L. ;
Shumaker, Amy Hirsch ;
Lavergne, Valery ;
Baden, Lindsey ;
Cheng, Vincent Chi-Chung ;
Edwards, Kathryn M. ;
Gandhi, Rajesh ;
Muller, William J. ;
O'Horo, John C. ;
Shoham, Shmuel ;
Murad, M. Hassan ;
Mustafa, Reem A. ;
Sultan, Shahnaz ;
Falck-Ytter, Yngve .
CLINICAL INFECTIOUS DISEASES, 2020, 78 (07) :e83-e102
[7]  
Bilich T, 2021, CANCER DISCOV, V11, P1982, DOI 10.1158/2159-8290.CD-21-0191
[8]  
Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI [10.1056/NEJMoa2001282, 10.1056/NEJMc2008043]
[9]   Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 [J].
Cavalcanti, A. B. ;
Zampieri, F. G. ;
Rosa, R. G. ;
Azevedo, L. C. P. ;
Veiga, V. C. ;
Avezum, A. ;
Damiani, L. P. ;
Marcadenti, A. ;
Kawano-Dourado, L. ;
Lisboa, T. ;
Junqueira, D. L. M. ;
de Barros e Silva, P. G. M. ;
Tramujas, L. ;
Abreu-Silva, E. O. ;
Laranjeira, L. N. ;
Soares, A. T. ;
Echenique, L. S. ;
Pereira, A. J. ;
Freitas, F. G. R. ;
Gebara, O. C. E. ;
Dantas, V. C. S. ;
Furtado, R. H. M. ;
Milan, E. P. ;
Golin, N. A. ;
Cardoso, F. F. ;
Maia, I. S. ;
Hoffmann Filho, C. R. ;
Kormann, A. P. M. ;
Amazonas, R. B. ;
Bocchi de Oliveira, M. F. ;
Serpa-Neto, A. ;
Falavigna, M. ;
Lopes, R. D. ;
Machado, F. R. ;
Berwanger, O. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (21) :2041-2052
[10]  
Corti D, 2021, CELL, V184, P3086, DOI [10.1016/j.cell.2021.05.005, 10.1016/j.cell.2021.07.027]